Resident Blog - Gillian Steiger episode artwork

EPISODE · May 15, 2026 · 11 MIN

Resident Blog - Gillian Steiger

from The mTOR You Know · host The mTOR You Know

PGY2 SOT Gillian Stiger joins us from the Hospital of the University of Pennsylvania to discuss “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study”, as well as a discussion on her residency experience with belatacept rapid conversion for a patient with thrombotic microangiopathy associated with tacrolimus.

PGY2 SOT Gillian Stiger joins us from the Hospital of the University of Pennsylvania to discuss “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study”, as well as a discussion on her residency experience with belatacept rapid conversion for a patient with thrombotic microangiopathy associated with tacrolimus.

NOW PLAYING

Resident Blog - Gillian Steiger

0:00 11:42

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The mTOR You Know?

This episode is 11 minutes long.

When was this The mTOR You Know episode published?

This episode was published on May 15, 2026.

What is this episode about?

PGY2 SOT Gillian Stiger joins us from the Hospital of the University of Pennsylvania to discuss “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized,...

Can I download this The mTOR You Know episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!